Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)

Cancer Immunol Immunother. 1998 Jun;46(4):201-12. doi: 10.1007/s002620050479.


Intravenous injection of the murine monoclonal anti-CA125 antibody B43.13 (Ovarex: Ab1) into ovarian cancer patients led to the induction of an idiotypic network. Of the 75 patients who received one to ten injections of a 2-mg dose of the antibody, 48 developed anti-(mAb B43.13) antibodies (Ab2); 18 of these patients also had elevated levels of anti-[anti-(mAb B43.13)] antibodies (Ab3; = anti-CA125 antibodies) compared to pre-injection values. Characterization of these antibodies revealed that the binding to CA125 could be inhibited by mAb B43.13 in most samples. Human anti-CA125 antibodies or Ab3 purified from patient serum samples specifically recognized human ovarian tumor cells and tissues expressing CA125. In addition, these anti-CA125 antibodies were able to conduct Fc-mediated tumor cell killing (antibody-dependent cell-mediated cytotoxicity). This raises the possibility of using an Ab1 for anti-idiotype induction immunotherapy of cancer.

MeSH terms

  • Animals
  • Antibodies, Anti-Idiotypic / biosynthesis*
  • Antibodies, Anti-Idiotypic / blood
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Neoplasm / biosynthesis*
  • Antibodies, Neoplasm / blood
  • Antibody-Dependent Cell Cytotoxicity / immunology
  • CA-125 Antigen / blood
  • CA-125 Antigen / immunology*
  • CA-125 Antigen / isolation & purification
  • Female
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Ovarian Neoplasms / blood
  • Ovarian Neoplasms / immunology
  • Ovarian Neoplasms / therapy*
  • Rabbits
  • Tumor Cells, Cultured


  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antibodies, Neoplasm
  • CA-125 Antigen